Amoeba: 11/15/21 – Postponement of the conclusion of the evaluation of the biocide dossier

PRESS RELEASE

The Maltese authority announces to Amoeba the conclusion of the evaluation of the dossier for the active biocidal substance at the end of March 2022.

Chassieu (France), November 15e, 2021 – 5:45 p.m. – AMOÉBA (FR0011051598 – ALMIB), producer of a biological biocide capable of eliminating the bacterial risk in water and human wounds, and of a biocontrol product for plant protection, still in the development phase, announces a postponement of the conclusion of the evaluation by Malta of the dossier for the active biocidal substance.

In July 2021 (see press release of July 5e, 2021), the Maltese authority informed Amoéba that the assessment report would be available by the end of 2021. Today, the Maltese authority informed the company that the assessment deadline will be extended and that the evaluation report will be submitted to the company by March 31st, 2022.

About AMOEBA:

Amoéba’s ambition is to become a major player in the treatment of bacterial risk in the fields of water, health and plant protection. Our biological solution is an alternative to chemicals widely used today. Amoéba is currently focusing on the industrial cooling tower market estimated at € 1.7 billion (1) on a global market for chemical biocides for water treatment, valued at € 21 billion (2) and on the biocontrol for plant protection estimated overall at € 1.6 billion (4). In the future, the Company plans to develop new applications such as chronic wound care, estimated at 751 million euros (3) in the USA. Sales of products associated with health, biocides and crop protection are subject to the granting of local regulatory marketing authorizations to the Company. The Company is currently in the testing phase for biocidal and phytosanitary applications and does not market any product.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada and the United States, Amoéba is listed on Euronext Growth. The Company is a member of the BPIfrance Excellence network and is eligible for the PEA-PME PME scheme. More information on www.amoeba-nature.com.

(1): Amoéba data grouped together from sources: DRIRE 2013, Eurostat, ARHIA 2013

(2): Sources grouped by Amoéba with water purifiers, Freedonia, Eurostat and MarketsandMarkets

(3): BCC Research, “Markets for Advanced Wound Management Technologies”, Wellesley, MA, 2017

(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, United Kingdom

Disclaimer

This press release contains certain forward-looking statements regarding AMOEBA which are based on its own assumptions and assumptions and on the information available to us. However, AMOEBA gives no assurance that the estimates contained in these forward-looking statements will be verified, which estimates are subject to numerous risks, including the risks set forth in the Universal Registration Document of AMOEBA filed with the AMOEBA. Autorité des Marchés Financiers Financiers) on April 12, 2021 under number D21-0289 (a copy of which is available at www.amoeba-biocide.com). The forward-looking statements contained in this press release are also subject to risks not yet known to AMOEBA or currently considered not to be material by AMOEBA. The occurrence of all or part of these risks could cause the actual results, financial conditions, performance or achievements of AMOEBA to differ materially from these forward-looking statements.